Article
Hematology
Laurent Garderet, Frederique Kuhnowski, Benoit Berge, Murielle Roussel, Laure Devlamynck, Marie Odile Petillon, Martine Escoffre-Barbe, Ingrid Lafon, Thierry Facon, Xavier Leleu, Lionel Karlin, Aurore Perrot, Anne-Marie Stoppa, Bruno Royer, Carine Chaleteix, Mourad Tiab, Carla Araujo, Pascal Lenain, Margaret Macro, Karim Belhadj, Souhila Ikhlef, Cyrille Hulin, Herve Avet Loiseau, Michel Attal, Philippe Moreau
Summary: Lenalidomide maintenance is the standard treatment for myeloma, but pomalidomide could be an alternative. A study showed that one third of myeloma patients in first relapse had an improved response to treatment with PCD therapy, including pomalidomide plus cyclophosphamide plus dexamethasone.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Immunology
Elham Roshandel, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Saeid Abroun, Reza Mirfakhraie, Abbas Hajifathali
Summary: Recent advances in adoptive cell therapy have transformed cancer immunotherapy, with a focus on treating relapsed/refractory multiple myeloma (RR/MM) using natural killer (NK) cells. NK cells exhibit effective cytotoxic activity against myeloma cells and can be derived from the patient or allogenic donors for therapy. Novel cell-based products, such as NK cell lines and CAR-NK cells, offer promising options for off-the-shelf NK cell therapy in MM.
CLINICAL IMMUNOLOGY
(2023)
Review
Immunology
Anne Marit Sponaas, Anders Waage, Esten N. Vandsemb, Kristine Misund, Magne Borset, Anders Sundan, Tobias Schmidt Slordahl, Therese Standal
Summary: This review article focuses on the role of memory T cells in multiple myeloma and how they can influence immune responses in patients receiving immunomodulating drugs and checkpoint therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Norbert Grzasko, Grzegorz Charlinski, Marta Morawska, Pawel Kicinski, Anna Waszczuk-Gajda, Joanna Drozd-Sokolowska, Edyta Subocz, Danuta Blonska, Malgorzata Razny, Agnieszka Druzd-Sitek, Jadwiga Holojda, Alina Swiderska, Lidia Usnarska-Zubkiewicz, Anna Masternak, Krzysztof Giannopoulos
Summary: This study suggests that bendamustine may be an effective treatment for patients with refractory/relapsed multiple myeloma. Three-drug regimens containing bendamustine, steroids, and novel agents produced better outcomes and had acceptable toxicity. The efficacy of bendamustine combined with steroids was limited.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Immunology
Priyanka S. S. Rana, Elena V. V. Murphy, Jeries Kort, James J. J. Driscoll
Summary: Genetically-reprogrammed T-cells have been successfully used as living drugs to treat human diseases. However, CAR T-cells face challenges such as antigen escape and T-cell exhaustion. Novel strategies are being developed to overcome these limitations and improve the efficacy of CAR T-cell therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Summary: Multiple Myeloma (MM) is a common cancer of the bone marrow that remains incurable despite advancements in therapy. While Daratumumab has improved survival rates, heavily pretreated patients who progress on this treatment have poor clinical outcomes. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be a viable treatment option for selected patients who are refractory to Daratumumab.
Article
Oncology
Hazim S. Ababneh, Andrew J. Yee, Noopur S. Raje, Sidney Martin, Matthew J. Frigault, Andrea K. Ng, Chirayu G. Patel
Summary: Radiation therapy (RT) may play a significant role in multiple myeloma (MM) before and after BCMA-targeted CAR T-cell therapy. This study observed 13 patients and found that RT as a bridging and salvage strategy is safe and effective in achieving local control in MM patients treated with CAR T-cell therapy.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Immunology
Leora S. Boussi, Zachary M. Avigan, Jacalyn Rosenblatt
Summary: Despite advances in treatment for multiple myeloma, understanding the mechanisms of immune evasion and resistance to therapy is critical for developing more effective treatments. Cellular adoptive therapy, particularly CAR T cell therapy, has shown promising results in refractory cases and may be a viable option for treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Matthew Ho, Saurabh Zanwar, Prashant Kapoor, Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, David Dingli, Francis Baudi, Eli Muchtar, Nelson Leung, Taxiarchis Kourelis, Rahma Warsame, Amie Fonder, Lisa Hwa, Miriam Hobbs, Robert Kyle, S. Vincent Rajkumar, Shaji Kumar
Summary: This study suggests that MM patients receiving >= 3 years of lenalidomide maintenance post-ASCT have superior outcomes. Lenalidomide refractoriness at first relapse is associated with inferior survival. At first relapse post-maintenance, daratumumab-based regimens show better survival outcomes.
BLOOD CANCER JOURNAL
(2021)
Review
Oncology
Ilaria Saltarella, Concetta Altamura, Carmen Campanale, Paola Laghetti, Angelo Vacca, Maria Antonia Frassanito, Jean-Francois Desaphy
Summary: Angiogenesis is a critical factor in multiple myeloma, affecting patients' prognosis, survival, and drug resistance. Various anti-angiogenic drugs targeting angiogenic cytokines and their receptors have been developed, along with standard antimyeloma drugs that also exhibit anti-angiogenic effects. This review examines the pharmacological profile and in vitro and in vivo anti-angiogenic effects of these therapies. Although direct targeting of angiogenic cytokines/receptors has shown limited efficacy, there is a need for a deeper understanding of the bone marrow angiogenic niche to develop novel multi-targeting anti-angiogenic therapies.
Review
Chemistry, Medicinal
Guoyuan Tang, Shan Huang, Ji Luo, Yingmiao Wu, Shuai Zheng, Rongsheng Tong, Ling Zhong, Jianyou Shi
Summary: This review article summarizes the characteristics, clinical investigations, and future development directions of multiple myeloma drugs, including their structures, mechanisms of action, clinical study progress, and the potential applications of drugs that have not yet entered clinical trials.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Oncology
Grzegorz Charlinski, David H. Vesole, Artur Jurczyszyn
Summary: Immunomodulatory drugs (IMiDs), due to their complex mechanism of actions, are a primary drug class used to treat multiple myeloma (MM). The standard of care currently involves combining IMiDs with corticosteroids and other drugs to improve outcomes in MM patients. Recent clinical trials have shown the effectiveness of newer cereblon inhibitors in MM treatment, even in cases refractory to approved IMiDs.
Article
Biotechnology & Applied Microbiology
Li Du, Wei Liu, Flavia Pichiorri, Steven T. Rosen
Summary: This study identified SUMOylation as a potential mechanism regulating lenalidomide resistance in multiple myeloma. Inhibition of SUMOylation can enhance sensitivity to lenalidomide by downregulating IRF4 expression.
CANCER GENE THERAPY
(2023)
Article
Hematology
Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M. Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, K. Martin Kortuem, Carsten Mueller-Tidow, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Niels Weinhold, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab
Summary: This article reports a clinical trial targeting patients with BRAFV600E-mutated relapsed/refractory multiple myeloma (RRMM), using the combination of BRAF/MEK inhibitors encorafenib and binimetinib. The results demonstrate that this treatment approach is highly effective and safe in RRMM patients.
Article
Oncology
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Mueller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel
Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.
Article
Hematology
Alessandra Larocca, Roberto Mina, Massimo Offidani, Anna Marina Liberati, Antonio Ledda, Francesca Patriarca, Andrea Evangelista, Stefano Spada, Giulia Benevolo, Daniela Oddolo, Vanessa Innao, Clotilde Cangiolosi, Annalisa Bernardini, Pellegrino Musto, Valeria Amico, Vincenzo Fraticelli, Laura Paris, Nicola Giuliani, Antonietta Pia Falcone, Renato Zambello, Lorenzo De Paoli, Alessandra Romano, Antonio Palumbo, Vittorio Montefusco, Roman Hajek, Mario Boccadoro, Sara Bringhen
Review
Oncology
Francesca Bonello, Roberto Mina, Mario Boccadoro, Francesca Gay
Review
Oncology
Candida Vitale, Maria Chiara Montalbano, Chiara Salvetti, Elia Boccellato, Valentina Griggio, Mario Boccadoro, Marta Coscia
Review
Oncology
Stefania Oliva, Mattia D'Agostino, Mario Boccadoro, Alessandra Larocca
FRONTIERS IN ONCOLOGY
(2020)
Review
Oncology
Evangelos Terpos, Monika Engelhardt, Gordon Cook, Francesca Gay, Maria-Victoria Mateos, Ioannis Ntanasis-Stathopoulos, Niels W. C. J. van de Donk, Herve Avet-Loiseau, Roman Hajek, Annette Juul Vangsted, Heinz Ludwig, Sonja Zweegman, Philippe Moreau, Hermann Einsele, Mario Boccadoro, Jesus San Miguel, Meletios A. Dimopoulos, Pieter Sonneveld
Letter
Oncology
Roberto Mina, Nisha S. Joseph, Francesca Gay, Efstathios Kastritis, Maria Teresa Petrucci, Jonathan L. Kaufman, Vittorio Montefusco, Maria Gavriatopoulou, Francesca Patriarca, Paola Omede, Lawrence H. Boise, Maria Roussou, Nicola Giuliani, Stefania Oliva, Massimo Offidani, Angelo Belotti, David L. Jaye, Lorenzo De Paoli, Evangelos Terpos, Sagar Lonial, Mario Boccadoro, Ajay K. Nooka, Meletios A. Dimopoulos
BLOOD CANCER JOURNAL
(2020)
Review
Oncology
Heinz Ludwig, Mario Boccadoro, Philippe Moreau, Jesus San-Miguel, Michele Cavo, Charlotte Pawlyn, Sonja Zweegman, Thierry Facon, Christoph Driessen, Roman Hajek, Melitios A. Dimopoulos, Francesca Gay, Herve Avet-Loiseau, Evangelos Terpos, Niklas Zojer, Mohamad Mohty, Maria-Victoria Mateos, Hermann Einsele, Michel Delforge, Jo Caers, Katja Weisel, Graham Jackson, Laurent Garderet, Monika Engelhardt, Niels van de Donk, Xavier Leleu, Hartmut Goldschmidt, Meral Beksac, Inger Nijhof, Niels Abildgaard, Sara Bringhen, Pieter Sonneveld
Summary: Vaccination is crucial for patients with multiple myeloma due to their increased risk of infections from immune suppression. Adequate measures should be taken to stimulate effective immune responses, and some patients may require a broader spectrum of vaccinations.
Review
Medicine, General & Internal
Giuseppina Ricciuti, Antonietta Falcone, Nicola Cascavilla, Giovanni Martinelli, Claudio Cerchione
Article
Oncology
Roman Hajek, Jiri Minarik, Jan Straub, Ludek Pour, Alexandra Jungova, Jesus G. Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A. Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L. Costello, Faith E. Davies, Vania T. M. Hungria, Hans C. Lee, Xavier Leleu, Noemi Puig, Robert M. Rifkin, Evangelos Terpos, Saad Z. Usmani, Katja C. Weisel, Jeffrey A. Zonder, Magda Barinova, Matyas Kuhn, Jiri Silar, Lenka Capkova, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren, Vladimir Maisnar
Summary: The study assessed the effectiveness and safety of using Ixazomib-Lenalidomide-Dexamethasone (IRd) in relapsed/refractory multiple myeloma patients, finding comparable results in routine clinical practice to those seen in clinical trials.
Letter
Oncology
Roberto Mina, Antonietta Pia Falcone, Sara Bringhen, Anna Marina Liberati, Norbert Pescosta, Maria Teresa Petrucci, Giovannino Ciccone, Andrea Capra, Francesca Patriarca, Delia Rota-Scalabrini, Francesca Bonello, Caterina Musolino, Michele Cea, Renato Zambello, Paola Tacchetti, Angelo Belotti, Claudia Cellini, Laura Paris, Mariella Grasso, Sara Aquino, Lorenzo De Paoli, Giovanni De Sabbata, Stelvio Ballanti, Massimo Offidani, Mario Boccadoro, Federico Monaco, Paolo Corradini, Alessandra Larocca
BLOOD CANCER JOURNAL
(2021)
Article
Hematology
G. Mele, N. Cascavilla, N. Di Renzo, A. Guarini, P. Mazza, L. Melillo, V. Pavone, G. Tarantini, P. Curci, A. P. Falcone, C. Germano, A. Mele, G. Palazzo, G. Palumbo, G. Reddiconto, B. Rossini, G. Specchia, P. Musto, D. Pastore
Summary: This multicenter retrospective analysis evaluated the efficacy of daratumumab in combination with bortezomib or lenalidomide as salvage therapy for symptomatic refractory/relapsed multiple myeloma patients. The overall response rate was lower than previous clinical trials, but encouraging results were observed in very old patients. Median time to progression and overall survival were promising in both treatment groups.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Enrica Antonia Martino, Concetta Conticello, Elena Zamagni, Vincenzo Pavone, Salvatore Palmieri, Maurizio Musso, Paola Tacchetti, Anna Mele, Lucio Catalano, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Iolanda Donatella Vincelli, Giuliana Farina, Marialucia Barone, Clotilde Cangialosi, Katia Mancuso, Ilaria Rizziello, Serena Rocchi, Antonietta Pia Falcone, Giuseppe Mele, Giovanni Reddiconto, Bruno Garibaldi, Enrico Iaccino, Giovanni Tripepi, Barbara Gamberi, Francesco Di Raimondo, Pellegrino Musto, Antonino Neri, Michele Cavo, Fortunato Morabito, Massimo Gentile
Summary: This study presents a retrospective multicenter analysis of 600 relapsed and refractory multiple myeloma patients treated with KRd therapy, revealing the safety and efficacy of KRd in clinical practice. Factors such as creatinine clearance<30 ml/min, >1 line of previous therapy, and high-risk FISH are associated with poor prognosis.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Oncology
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi, Roberto Ria, Lucio Catalano, Paola Tacchetti, Giuseppe Mele, Iolanda Donatella Vincelli, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Cirino Botta, Anna Mele, Lucia Pantani, Serena Rocchi, Bruno Garibaldi, Nicola Cascavilla, Stelvio Ballanti, Giovanni Tripepi, Ferdinando Frigeri, Antonetta Pia Falcone, Clotilde Cangialosi, Giovanni Reddiconto, Giuliana Farina, Marialucia Barone, Ilaria Rizzello, Enrico Iaccino, Selena Mimmi, Paola Curci, Barbara Gamberi, Pellegrino Musto, Valerio De Stefano, Maurizio Musso, Maria Teresa Petrucci, Massimo Offidani, Francesco Di Raimondo, Mario Boccadoro, Michele Cavo, Antonino Neri, Massimo Gentile
Summary: The present study developed two survival risk scores for relapsed/refractory multiple myeloma patients. The study found that several factors were associated with patients' survival and progression risks, and these risks could be classified using risk scores.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Anna Mele, Eleonora Prete, Clara De Risi, Stefania Citiso, Giuseppina Greco, Antonietta Pia Falcone, Grazia Sanpaolo, Giuseppe Mele, Angela Giannotta, Carolina Vergine, Giovanni Reddiconto, Giulia Palazzo, Sabrina Sabatelli, Candida Germano, Rosanna Miccolis, Paola Curci, Gaetano Palumbo, Massimo Offidani, Rita Rizzi, Nicola Cascavilla, Domenico Pastore, Nicola Di Renzo, Patrizio Mazza, Giuseppe Tarantini, Attilio Guarini, Silvana Capalbo, Giorgina Specchia, Antonino Greco, Rosa De Francesco, Silvia Sibilla, Lorenzo Tonialini, Maria Rosaria Morciano, Vincenzo Pavone
Summary: This retrospective study evaluated 130 consecutive RRMM patients treated with KRd, showing that KRd is effective and well-tolerated, serving as a bridge regimen to ASCT. Patients achieving VGPR, those naive to lenalidomide, and patients relapsing after ASCT demonstrated longer PFS.
ANNALS OF HEMATOLOGY
(2021)